FFR benefits lead St. Jude to halt FAME II study

01/23/2012 | MedCityNews.com · CardiologyToday.com

The FAME II trial was suspended after preliminary findings showed using fractional flow reserve technology in PCI for patients with coronary artery disease significantly reduced hospital readmissions and the need for urgent revascularization. The study's safety monitoring board said it would be unethical for St. Jude Medical to continue to randomly assign patients treatment without FFR.

View Full Article in:

MedCityNews.com · CardiologyToday.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN